American Association for Cancer Research

AACR Cancer Policy Monitor

Bookmark and Share
CPM
October 2011

 


 

ENDGAME UNCLEAR OVER FY2012 BUDGET AND NIH, NCI APPROPRIATIONS

Congressional leaders hope to approve spending bills by mid-November

With key deadlines quickly approaching, funding for cancer research and biomedical science remains uncertain and in jeopardy. Read more

 


 

FDA SEEKS INPUT ON COMPANION DIAGNOSTICS

AACR urges guidance on co-development process

This summer, the U.S. Food and Drug Administration (FDA) approved two new medicines for cancer: crizotinib (Xalkori) and vemurafenib (Zelboraf). These two medicines are examples of the shifting paradigm of drug development in which therapies are rationally designed to target the molecular defects found in particular cancer cells. Read more

 


 

OPPORTUNITIES TO SHAPE NATIONAL CER EFFORTS

Researchers, patients sought to help advance comparative effectiveness research

One of the major research-related provisions of health care reform was the expansion of federally-funded comparative effectiveness research (CER), which aims to better understand and compare the clinical merits of different treatments, devices and procedures. The 2010 law set up a new, non-governmental organization called the Patient-Centered Outcomes Research Institute (PCORI), which has a charter through 2019 to fund CER. While the organization has taken time to get off the ground, recent activity by PCORI provides researchers, as well as patients, opportunities to shape the future of this important field of research. Read more

 



Top